Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brimonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 20/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 19/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 19/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 15/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 13/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brimonidine SCHEMBL20511531 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL24670 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616115 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL1685506 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616188 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616237 | 0.91 | ADRA2A (0.83) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616205 | 0.90 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL20511553 | 0.89 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616277 | 0.89 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Brimonidine SCHEMBL22616267 | 0.88 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634415-B1 | OPHTHALMOLOGICAL COMPOSITIONS COMPRISING BRIMONIDINE AND KETOTIFEN FOR USE IN THE TREATMENT OF ALLERGIES | EYE THERAPIES LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4236932-B1 | DEGRADANT COMPOUND IN A MEDICAMENT | VISUS THERAPEUTICS INC (US) | 2026-01-07 | — | — | EP | claimed |
| EP-3706715-B1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF BRINZOLAMIDE AND BRIMONIDINE AND METHOD OF PREPARATION THEREOF | PHARMATHEN SA (GR) | 2025-11-05 | — | — | EP | claimed |
| US-12336986-B2 | Treatment and prevention of ocular neurodegenerative disorder | THE JACKSON LABORATORY (US) | 2025-06-24 | — | — | US | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| EP-3958889-B1 | COLLAGEN MIMETIC PEPTIDE COMPOSITIONS FOR TREATING A POSTERIOR SEGMENT OCULAR DISEASE OR DISORDER INVOLVING THE RETINA, RETINAL BLOOD VESSELS, RETINAL NERVES OR OPTIC NERVE | SUSTAIN HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | claimed |
| EP-3756665-B1 | INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES | UNIV RAMOT (IL) | 2024-08-14 | — | — | EP | claimed |
| EP-3654964-B1 | COMPOSITION COMPRISING ATROPINE AND A MIOTIC AGENT AND ITS USE IN THE TREATMENT OF MYOPIA | SEINDA PHARMACEUTICAL GUANGZHOU CORP (CN) | 2024-04-24 | — | — | EP | claimed |
| EP-3419622-B1 | TREATMENT OF NEURODEGENERATIVE EYE DISEASE USING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2024-03-06 | — | — | EP | claimed |
| US-20230404979-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2023-12-21 | — | — | US | claimed |
| EP-3685828-B1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION, OPHTHALMIC KIT, AND PHARMACEUTICAL APPLICATION THEREOF | SHENYANG XINGQI PHARMACEUTICAL CO LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| EP-3522914-B1 | VASOCONSTRICTIVE AND ANTIBACTERIAL COMBINATION TREATMENT FOR ROSACEA | MICREOS HUMAN HEALTH BV (NL) | 2023-03-08 | — | — | EP | claimed |
| EP-3261620-B1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | UNIV ILLINOIS (US) | 2022-11-09 | — | — | EP | claimed |
| EP-4031000-A1 | SYSTEMS AND METHODS FOR DETECTION AND PREVENTION OF EMERGENCE OF AGITATION | Bioxcel Therapeutics, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220202373-A1 | SYSTEMS AND METHODS OF USING MACHINE LEARNING TO DETECT AND PREDICT EMERGENCE OF AGITATION BASED ON SYMPATHETIC NERVOUS SYSTEM ACTIVITIES | BIOXCEL THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | US | claimed |
| CN-114667095-A | System and method for detecting and preventing irritability occurrences | 比奥克斯塞尔医疗股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| EP-2437684-B1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5 INC (US) | 2022-06-15 | — | — | EP | claimed |
| WO-2022103250-A1 | SYNERGISTIC OPHTHALMOLOGICAL COMPOSITION IN A LOW-CONCENTRATION DOSE THAT IS EFFECTIVE IN THE PREVENTION, CONTROL AND ERADICATION OF PRESBYOPIA | SANCHEZ GALEANA CESAR ALEJANDRO (MX) | 2022-05-19 | — | — | WO | claimed |
| WO-2022093767-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| CN-114401633-A | Pest control method, pest control agent composition, and pest control agent set | 日本曹达株式会社 | 2022-04-26 | — | — | CN | claimed |